These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24885453)

  • 21. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study.
    Scott CA; Iyer HS; McCoy K; Moyo C; Long L; Larson BA; Rosen S
    BMC Public Health; 2014 Mar; 14():296. PubMed ID: 24684772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.
    Ciaranello AL; Chang Y; Margulis AV; Bernstein A; Bassett IV; Losina E; Walensky RP
    Clin Infect Dis; 2009 Dec; 49(12):1915-27. PubMed ID: 19916798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Annual cost of antiretroviral therapy among three service delivery models in Uganda.
    Vu L; Waliggo S; Zieman B; Jani N; Buzaalirwa L; Okoboi S; Okal J; Borse NN; Kalibala S
    J Int AIDS Soc; 2016; 19(5 Suppl 4):20840. PubMed ID: 27443270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
    Werayingyong P; Phanuphak N; Chokephaibulkit K; Tantivess S; Kullert N; Tosanguan K; Butchon R; Voramongkol N; Boonsuk S; Pilasant S; Kulpeng W; Teerawattananon Y
    Asia Pac J Public Health; 2015 Mar; 27(2):NP866-76. PubMed ID: 23728769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A visual dosing aid for first-line pediatric antiretroviral treatment in resource-poor settings.
    Callens SF; Westreich D; Kitetele F; Lusiama J; Shabani N; Belhorn T; Colebunders R; Behets F; Van Rie A
    J Trop Pediatr; 2009 Apr; 55(2):135-7. PubMed ID: 19022850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium.
    Jesson J; Desmonde S; Yiannoutsos CT; Patten G; Malateste K; Duda SN; Kumarasamy N; Yotebieng M; Davies MA; Musick B; Leroy V; Ciaranello A;
    BMC Res Notes; 2020 May; 13(1):249. PubMed ID: 32448379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reliability of absolute lymphocyte count as a marker to assess the need to initiate antiretroviral therapy in HIV-infected children.
    Shah I; Parikh S
    J Postgrad Med; 2012; 58(3):176-9. PubMed ID: 23023348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients.
    Bouazza N; Urien S; Blanche S; Hirt D; Foissac F; Benaboud S; Tréluyer JM; Frange P
    Pediatr Infect Dis J; 2014 Aug; 33(8):e213-8. PubMed ID: 24509655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
    Mir F; Qamar FN; Baig-Ansari N; Abro AG; Abbas SQ; Kazi MA; Rizvi A; Zaidi AK
    J Infect Dev Ctries; 2014 Apr; 8(4):519-25. PubMed ID: 24727519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One world, one hope: the cost of providing antiretroviral therapy to all nations.
    Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
    AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring of antiretrovirals for people with HIV.
    Kredo T; Van der Walt JS; Siegfried N; Cohen K
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007268. PubMed ID: 19588422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
    Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL
    Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The urgent need for feasibility studies of antiretroviral treatment in HIV-infected individuals in resource-limited settings.
    van der Groen G
    AIDS; 2001 Nov; 15(17):2342-4. PubMed ID: 11698717
    [No Abstract]   [Full Text] [Related]  

  • 39. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age.
    Sauvageot D; Schaefer M; Olson D; Pujades-Rodriguez M; O'Brien DP
    Pediatrics; 2010 May; 125(5):e1039-47. PubMed ID: 20385636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.